The Margolis 1 refers to the subgroup of patients from the...

The Margolis 1 refers to the subgroup of patients from the vitrocard study. These are people whose wounds are moderate (being neither minor nor very severe). From analysis of the previous open label trial data (vitrocard) it was this group of people who were expected to gain the most from treatment. Margolis 0 would be expected to heal anyway, Margolis 2 were more severe to the point that they needed other specialist (more expensive) treatments that would occur in a clinical setting.

In regards to competition etc I believe that this is why the Margolis 1 subgroup was selected in the first place. At the start of the reclamation project (2015 onwards post TIS fiasco) I understand they performed a critical analysis of the product to confirm its relevance within the market place. My understanding is that this target group of patients are within the home care setting where a patient has their wound treated at home.

I believe that the company has been pretty clear and up front about where the product is targeted and even an approximate price point ($1000-1200 from memory). There are institutions prepared to support the company on the basis of the above.

I definitely feel for long term holders. I also held TIS shares at the time although only to a small degree. But for me personally the company now is a completely independent entity, that has been steered well post the resignation of the old guard (who should be hanging their heads in shame).